Therefore, we investigated whether administration of a CXCR4 inhibitor during the time of day when its expression is elevated on tumor‐infiltrated CD8+ T cells causes their dispersion from CAF‐dense regions throughout the tumors, and explored whether resolving intratumoral aggregation of CD8+ T cells could enhance the anti‐tumor immune activity of ICIs. The gene discussed is CXCR4; the disease is neoplasm.